Preliminary Clinical Method Comparison of a Point-of-Care Platform for anti-Factor Xa in Pediatric Patients on Heparin Therapy

Frequent monitoring for anti-Factor Xa activity (aFXa) and/or activated partial thromboplastin time (aPTT) is required for children receiving heparin therapy to achieve hemostatic balance. However, current heparin tests demand large blood volumes, potentially causing iatrogenic anemia.In this study, we present the preliminary results of a clinical method comparison (12/08/2022 – 6/15/2023) in collaboration with Children’s Healthcare of Atlanta. The study evaluates a rapid (~14-minute), point-of-care digital microfluidic (DMF) platform for aFXa testing. This platform operates directly from low whole blood sample volumes (<50 μL), and the results are compared against an FDA-cleared comparator